Antibody profile in systemic sclerosis patients: A cross-sectional study from Kashmir Valley of India
DOI:
https://doi.org/10.66344/jpad.v28i1.988Keywords:
Anti-centromere antibody, antinuclear antibody, anti-Scl70 antibody, systemic sclerosisAbstract
Objective This study aimed to find the prevalence of the most common antibodies in patients of systemic sclerosis and to ascertain their prevalence with the limited and diffuse cutaneous variants of systemic sclerosis.
Methods Thirty-four patients of systemic sclerosis, attending the dermatology department, diagnosed as per the American Rheumatology Association criteria were recruited for this cross-sectional study. They were classified as having limited and diffuse systemic sclerosis. All patients were subjected to serum estimations of antinuclear antibodies, anticentromere antibodies and anti-Scl70 antibodies. The results were tabulated and analyzed for possible association between disease subsets and antibodies.
Results There were 27 patients with limited disease and 7 with diffuse disease. Antinuclear antibodies were seen in 76.5% of all patients. Anticentromere antibodies were seen in 9 (33.3%) limited disease patients and 1 (14.3%) in diffuse variant. The total prevalence of anticentromere antibodies was 29.4%. Anti-Scl70 antibodies were found in 5 (18.6%) and 3 (42.9%) patients of limited and diffuse disease subset, respectively. Overall, these antibodies were seen in 23.5% patients.
Conclusion Anticentromere antibodies are more common in limited systemic sclerosis while anti-Scl70 antibodies are seen more frequently in diffuse systemic sclerosis. Thus, these antibodies can act as a marker of future disease activity, severity of disease and prognosis.
References
1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67.
2. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy and environmental triggers. Curr Opin Rheumatol. 2012;24:165-70.
3. Orteu CH, Denton CP. Systemic Sclerosis. In: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. West Sussex (UK); Wiley-Blackwell: 2016. p.56.1-23.
4. Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015;15:24.
5. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol. 2009;21:617-22.
6. Kraaij MD, Van Laar JM. The role of B cells in systemic sclerosis. Biologics. 2008;2:389-95.
7. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15:102-9.
8. Hasegawa M. Biomarkers in systemic sclerosis: Their potential to predict clinical courses. J Dermatol. 2016;43:29-38.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:58-90.
10. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223-35.
11. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9:A311-8.
12. Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai. 2002;85:1204-9.
13. Sharma VK, Trilokraj T, Khaitan BK, Krishna SM. Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol. 2006;72:416-20.
14. Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B. Esophageal involvement in scleroderma: Clinical, endoscopic, and manometric features. ISRN Rheumatol. 2011;2011:1-5.
15. Arias Nunez M, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J et al. Systemic sclerosis in northwestern Spain: a 19 year epidemiologic study. Medicine. 2008;87:272-80.
16. Schneeberger D, Tyndall A, Kay J, Sondergaard KH, Carriera PE, Morgiel E et al. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: a multicenter study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013;52:560-7.
17. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008;158:487-95.
18. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol. 2007;19:580-91.
19. Admou B, Arji N, Seghrouchni F, Missoum H, El Fenniri L, Amghar S et al. Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases). Ann Biol Clin (Paris). 2007;65:291-7.
20. Giddon AE, Dore CJ, Dunphy J, Betteridge Z, McHugh NJ, Paddison PJ et al. Antinuclear antibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. J Rheumatol. 2011;38:702-5.
21. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA. Disease subsets, antinuclear antibody profile and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34:104-9.
22. Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012;43:249-55.
23. Müller CS, Paiva ES, Azevedo VF, Radominski SC, Lima Filho JHC. Perfil de autoanticorpos e correlac¸ão clínica em umgrupo de pacientes com esclerose sistêmica na região Sul doBrasil. Rev Bras Rheumatol. 2011;51:319-24.
24. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55.
25. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42-53.
26. Horimoto AMC, da Costa IP. Antibodies in systemic sclerosis and their clinical correlation in patients from a midwestern region of Brazil. Rev Bras Rheumatol. 2015;55:229-39.
27. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340-54.
28. Behmanesh F, Amin R, Khajedaluee M, Fritzler MJ. Antibody profile in systemic sclerosis. Acta Medica Iranica. 2010;48:12-20.
29. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nature Rev Rheumatol. 2010;6:112-6.
30. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011;13:R211.
31. Vanthuyne M, Smith V, De Langhe E, Praet JV, Arat S, Depresseux G et al. The Belgian systemic sclerosis cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol. 2012;39:2127-33.
32. Fritsch S, Pizzol VID, Paiva ES, Muller CS. Autoantibodies coexistence in systemic sclerosis: how to interpret it. Rev Bras Rheumatol. 2012;52:949-55.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Tasleem Arif, Mohammad Adil, Iffat Hassan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
